Marijuana-based drug specialist GW Pharmaceuticals is emerging as a takeover target, according to press reports, as big pharma companies seek to buy its key epilepsy medicine. GW's shares soared ...

“It’s a huge breakthrough for the concept of cannabinoids as medicines,” says Justin Gover, CEO of manufacturer GW Pharmaceuticals. Next, the company is exploring how effective CBD and other ...

Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately ...

GW Pharmaceuticals' Epidyolex has been approved in the EU for a third epilepsy indication, giving a boost for the company ahead of its $7.2 billion takeover by Jazz Pharma.

Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter ... was the centerpiece of its $7.2 billion buyout of GW Pharmaceuticals in 2021. As one analyst noted ...

Jazz Pharmaceuticals JAZZ has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ...

In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. Market Capitalization Analysis: Reflecting a smaller ...

Simon Thompson: It is rated on a 2026 PE ratio of 10 even though the integration of bolt-on acquisiti ...

All the articles published in this week's magazine in one place ...

GW Pharmaceuticals is a cutting-edge UK-based biopharmaceutical company that over the last 20 years has established a world-leading position in cannabinoid science and the development of ...